214 related articles for article (PubMed ID: 15157211)
1. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
[TBL] [Abstract][Full Text] [Related]
2. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.
Satoh M; Kloth DM; Kadhim SA; Chin JL; Naganuma A; Imura N; Cherian MG
Cancer Res; 1993 Apr; 53(8):1829-32. PubMed ID: 8467502
[TBL] [Abstract][Full Text] [Related]
3. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.
Satoh M; Cherian MG; Imura N; Shimizu H
Cancer Res; 1994 Oct; 54(20):5255-7. PubMed ID: 7923149
[TBL] [Abstract][Full Text] [Related]
4. Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein.
Kondo Y; Yamagata K; Satoh M; Himeno S; Imura N; Nishimura T
J Urol; 2003 Dec; 170(6 Pt 1):2467-70. PubMed ID: 14634452
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
6. [Role of metallothionein in cancer chemotherapy].
Naganuma A; Imura N
Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of interleukin-12 against murine bladder cancer.
Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to radiation treatment and changes in metallothionein synthesis in a transplanted murine tumor.
Shibuya K; Cherian MG; Satoh M
Radiat Res; 1997 Sep; 148(3):235-9. PubMed ID: 9291354
[TBL] [Abstract][Full Text] [Related]
9. Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice.
Okazaki Y; Miura N; Satoh M; Imura N; Naganuma A
Biochem Biophys Res Commun; 1998 Apr; 245(3):815-8. PubMed ID: 9588197
[TBL] [Abstract][Full Text] [Related]
10. [Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)].
Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Kamizuru M; Wada S; Hayahara M
Hinyokika Kiyo; 1992 Mar; 38(3):285-9. PubMed ID: 1523983
[TBL] [Abstract][Full Text] [Related]
11. Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice.
Lee K; O'Donnell RW; Marquis D; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):32-42. PubMed ID: 3286824
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide.
Borden EC; Sidky YA; Groveman DS; Bryan GT
Cancer Res; 1985 Jan; 45(1):45-50. PubMed ID: 3965150
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor.
Kondo Y; Satoh M; Imura N; Akimoto M
Anticancer Res; 1992; 12(6B):2303-7. PubMed ID: 1295477
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein gene expression in bladder cancer exposed to cisplatin.
Wood DP; Klein E; Fair WR; Chaganti RS
Mod Pathol; 1993 Jan; 6(1):33-5. PubMed ID: 8426855
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities.
Byun SS; Kim SW; Choi H; Lee C; Lee E
BJU Int; 2005 May; 95(7):1086-90. PubMed ID: 15839938
[TBL] [Abstract][Full Text] [Related]
17. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
[TBL] [Abstract][Full Text] [Related]
18. [Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer].
Liang Z; Bian D
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):75-8. PubMed ID: 8758797
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed.
Khandaker MH; Kadhim SA; Ichim TE; Howson-Jan K; Chin J; Singhal SK
Anticancer Res; 2000; 20(1A):183-9. PubMed ID: 10769653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
